| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 11/18/2020 | 3. Issuer Name and Ticker or Trading Symbol PLx Pharma Inc. [ PLXP ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock, $0.001 par value | 1,320,306(1)(2) | D | |
| Common Stock, $0.001 par value | 875,000(2) | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Warrants (right to buy) | 11/18/2020 | 11/18/2025 | Common Stock | 1,452,337(3) | 4.31 | D | |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. Level One Partners, LLC (the "Reporting Person") is owned by Robert D. Hardie ("Mr. Hardie") and Molly G. Hardie ("Ms. Hardie"), who are married. Mr. Hardie is the manager of the Reporting Person and also holds shares of PLx Pharma Inc. (the "Company") individually. |
| 2. As of the date of this report, the Reporting Person holds 1,320,306 shares of Common Stock, $.001 par value per share (the "Common Stock") of the Company, and Mr. Hardie holds 875,000 shares of Common Stock of the Company. Pursuant to 17 CFR Section 240.16a-1(a)(2), Ms. Hardie's beneficial ownership is limited to her pecuniary interest, if any, in such securities. |
| 3. As of the date of this report, the Reporting Person holds warrants to purchase 1,452,337 shares of Common Stock. |
| Robert D. Hardie, Manager of Level One Partners, LLC | 03/12/2021 | |
| Robert D. Hardie | 03/12/2021 | |
| Molly G. Hardie | 03/12/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
